Impact of mass administration of azithromycin as a preventive treatment on the prevalence and resistance of nasopharyngeal carriage of Staphylococcus aureus.
Anti-Bacterial Agents
/ administration & dosage
Antimalarials
/ administration & dosage
Azithromycin
/ administration & dosage
Child, Preschool
Drug Resistance, Bacterial
/ drug effects
Female
Humans
Infant
Malaria
/ prevention & control
Male
Nasopharynx
/ microbiology
Prevalence
Staphylococcal Infections
/ diagnosis
Staphylococcus aureus
/ drug effects
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
12
2020
accepted:
27
07
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
25
11
2021
Statut:
epublish
Résumé
Staphylococcus aureus is a major cause of serious illness and death in children, indicating the need to monitor prevalent strains, particularly in the vulnerable pediatric population. Nasal carriage of S. aureus is important as carriers have an increased risk of serious illness due to systemic invasion by this pathogen and can transmit the infection. Recent studies have demonstrated the effectiveness of azithromycin in reducing the prevalence of nasopharyngeal carrying of pneumococci, which are often implicated in respiratory infections in children. However, very few studies of the impact of azithromycin on staphylococci have been undertaken. During a clinical trial under taken in 2016, nasal swabs were collected from 778 children aged 3 to 59 months including 385 children who were swabbed before administration of azithromycin or placebo and 393 after administration of azithromycin or placebo. Azithromycin was given in a dose of 100 mg for three days, together with the antimalarials sulfadoxine-pyrimethamine and amodiaquine, on four occasions at monthly intervals during the malaria transmission season. These samples were cultured for S. aureus as well as for the pneumococcus. The S. aureus isolates were tested for their susceptibility to azithromycin (15 g), penicillin (10 IU), and cefoxitine (30 g) (Oxoid Ltd). S. aureus was isolated from 13.77% (53/385) swabs before administration of azithromycin and from 20.10% (79/393) six months after administration (PR = 1.46 [1.06; 2.01], p = 0.020). Azithromycin resistance found in isolates of S. aureus did not differ significantly before and after intervention (26.42% [14/53] vs 16.46% [13/79], (PR = 0.62 [0.32; 1.23], p = 0.172). Penicillin resistance was very pronounced, 88.68% and 96.20% in pre-intervention and in post-intervention isolates respectively, but very little Methicillin Resistance (MRSA) was detected (2 cases before and 2 cases after intervention). Monitoring antibiotic resistance in S. aureus and other bacteria is especially important in Burkina Faso due to unregulated consumption of antibiotics putting children and others at risk.
Identifiants
pubmed: 34644317
doi: 10.1371/journal.pone.0257190
pii: PONE-D-20-33805
pmc: PMC8513893
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antimalarials
0
Azithromycin
83905-01-5
Banques de données
ClinicalTrials.gov
['NCT02211729']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0257190Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
N Engl J Med. 2019 Jun 06;380(23):2271-2273
pubmed: 31167060
PLoS One. 2017 Jan 20;12(1):e0170320
pubmed: 28107412
Med Sante Trop. 2012 Oct-Dec;22(4):425-9
pubmed: 23360620
N Engl J Med. 2020 Nov 12;383(20):1941-1950
pubmed: 33176084
Clin Infect Dis. 2013 Jun;56(11):1519-26
pubmed: 23487375
Antimicrob Agents Chemother. 2003 Sep;47(9):2765-9
pubmed: 12936971
Br J Ophthalmol. 2003 Feb;87(2):147-8
pubmed: 12543738
Lancet Infect Dis. 2016 Jun;16(6):703-711
pubmed: 26897105
Pediatr Infect Dis J. 1999 Oct;18(10 Suppl):S35-41
pubmed: 10530572
N Engl J Med. 2019 Jun 06;380(23):2197-2206
pubmed: 30699301
BMC Res Notes. 2017 Dec 19;10(1):746
pubmed: 29258622
BMC Infect Dis. 2019 Dec 2;19(1):1023
pubmed: 31791276
Bull World Health Organ. 2014 Jul 1;92(7):490-8
pubmed: 25110374
Clin Infect Dis. 1997 Mar;24(3):356-62
pubmed: 9114185
J Pediatr. 2013 Jul;163(1 Suppl):S4-7
pubmed: 23773593
Emerg Infect Dis. 2019 Apr;25(4):701-709
pubmed: 30882307
Trop Med Int Health. 2019 Dec;24(12):1442-1454
pubmed: 31655020
JAMA. 2009 Sep 2;302(9):962-8
pubmed: 19724043
Clin Infect Dis. 2011 Apr 1;52(7):883-8
pubmed: 21427395